Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1981 2
1982 3
1983 3
1984 6
1985 2
1986 3
1987 5
1988 3
1989 8
1990 12
1991 7
1992 10
1993 6
1994 14
1995 14
1996 10
1997 13
1998 17
1999 24
2000 24
2001 43
2002 48
2003 54
2004 64
2005 86
2006 98
2007 119
2008 127
2009 148
2010 149
2011 138
2012 186
2013 199
2014 299
2015 328
2016 321
2017 379
2018 383
2019 416
2020 523
2021 608
2022 714
2023 98
Text availability
Article attribute
Article type
Publication date

Search Results

5,143 results
Results by year
Filters applied: . Clear all
Page 1
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.
Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Daniel B, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT. Belk JA, et al. Among authors: yao w. Cancer Cell. 2022 Jul 11;40(7):768-786.e7. doi: 10.1016/j.ccell.2022.06.001. Epub 2022 Jun 23. Cancer Cell. 2022. PMID: 35750052
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: yao w. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, Belk JA, Ross KN, Sheffer M, Linde MH, Ly N, Yao W, Rotiroti MC, Smith BAH, Wernig M, Bertozzi CR, Monje M, Mitsiades CS, Majeti R, Satpathy AT, Stegmaier K, Majzner RG. Mabe NW, et al. Among authors: yao w. Nat Cancer. 2022 Aug;3(8):976-993. doi: 10.1038/s43018-022-00405-x. Epub 2022 Jul 11. Nat Cancer. 2022. PMID: 35817829
CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.
Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, Luo Y, Fang J, Yang X, Huang Q, Xu L, Guo J, Wen S, Wang Z, Wu Q, Tang J, Wang L, Chen X, Chen C, Zhang Y, Yao W, Ye J, He R, Huang J, Ye L. Xiao M, et al. Among authors: yao w. J Immunother Cancer. 2022 May;10(5):e004022. doi: 10.1136/jitc-2021-004022. J Immunother Cancer. 2022. PMID: 35580929 Free PMC article.
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Koblish HK, Wu L, Wang LS, Liu PCC, Wynn R, Rios-Doria J, Spitz S, Liu H, Volgina A, Zolotarjova N, Kapilashrami K, Behshad E, Covington M, Yang YO, Li J, Diamond S, Soloviev M, O'Hayer K, Rubin S, Kanellopoulou C, Yang G, Rupar M, DiMatteo D, Lin L, Stevens C, Zhang Y, Thekkat P, Geschwindt R, Marando C, Yeleswaram S, Jackson J, Scherle P, Huber R, Yao W, Hollis G. Koblish HK, et al. Among authors: yao w. Cancer Discov. 2022 Jun 2;12(6):1482-1499. doi: 10.1158/2159-8290.CD-21-1156. Cancer Discov. 2022. PMID: 35254416 Free PMC article. Clinical Trial.
5,143 results